In an unintended consequence of the new healthcare law, drug companies have begun notifying children’s hospitals around the country that they no longer qualify for large discounts on drugs used to treat rare medical conditions. As a result, prices are going up for these specialized “orphan drugs,” some of which are also used to treat more common conditions. Over the last 18 years, Congress has required drug manufacturers to provide discounts to a variety of health care providers, including community health centers, AIDS clinics and hospitals that care for large numbers of low-income people.